Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) EBITDA Margin (2021 - 2025)

Oncology Institute's EBITDA Margin history spans 5 years, with the latest figure at 4.22% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 675.0% year-over-year to 4.22%; the TTM value through Dec 2025 reached 6.39%, up 808.0%, while the annual FY2025 figure was 6.39%, 808.0% up from the prior year.
  • EBITDA Margin reached 4.22% in Q4 2025 per TOI's latest filing, up from 5.16% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1.89% in Q2 2021 to a low of 77.56% in Q4 2021.
  • Average EBITDA Margin over 5 years is 19.56%, with a median of 15.85% recorded in 2024.
  • The largest YoY upside for EBITDA Margin was 4310bps in 2022 against a maximum downside of -2965bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 77.56% in 2021, then skyrocketed by 56bps to 34.47% in 2022, then soared by 51bps to 16.88% in 2023, then skyrocketed by 35bps to 10.97% in 2024, then surged by 62bps to 4.22% in 2025.
  • Per Business Quant, the three most recent readings for TOI's EBITDA Margin are 4.22% (Q4 2025), 5.16% (Q3 2025), and 8.5% (Q2 2025).